BCAX

Bicara Therapeutics Inc

Add to Watchlist

Advanced Chart

11.940

+0.03(0.252%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

12.005

Open

11.930

VWAP

11.85

Vol

189.26K

Mkt Cap

651.48M

Low

11.600

Amount

2.24M

EV/EBITDA(TTM)

Total Shares

54.54M

214.56M

EV/OCF(TTM)

P/S(TTM)

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.

6 Analyst Rating

177.81% Upside

Wall Street analysts forecast BCAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAX is 33.17 USD with a low forecast of 8.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

177.81% Upside

Current: 11.940

Low

8.00

Averages

33.17

High

48.00

177.81% Upside

Current: 11.940

Low

8.00

Averages

33.17

High

48.00

H.C. Wainwright

Robert Burns

Buy

downgrade

$41 -> $40

2025-08-22

Reason

H.C. Wainwright

Robert Burns

Price Target

$41 -> $40

2025-08-22

downgrade

Buy

Reason

H.C. Wainwright analyst Robert Burns lowered the firm's price target on Bicara Therapeutics to $40 from $41 and keeps a Buy rating on the shares following the Q2 report. The firm is factoring in higher long-term operating expenses.

Piper Sandler

Kelsey Goodwin

Overweight

initiated

$36

2025-08-19

Reason

Piper Sandler

Kelsey Goodwin

Price Target

$36

2025-08-19

initiated

Overweight

Reason

Piper Sandler analyst Kelsey Goodwin initiated coverage of Bicara Therapeutics with an Overweight rating and $36 price target. The firm's channel checks highlighted a favorable view on Bicara's patient selection strategy for the pivotal FORTIFi-HN01, ficera's potentially differentiated mDOR, the importance of continued follow-up in relapsed metastatic head and neck squamous cell cancer, and the overall perception that the large market will likely be split longer term, the analyst tells investors in a research note. Piper sees the recent pullback as offering a highly attractive entry point.

Piper Sandler

Kelsey Goodwin

initiated

$36

2025-08-18

Reason

Piper Sandler

Kelsey Goodwin

Price Target

$36

2025-08-18

initiated

Reason

Piper Sandler analyst Kelsey Goodwin initiated coverage of Bicara Therapeutics with an Overweight rating and $36 price target.

Wells Fargo

Eva Fortea Verdejo

Underweight -> Equal Weight

upgrade

2025-05-23

Reason

Wells Fargo

Eva Fortea Verdejo

Price Target

2025-05-23

upgrade

Underweight -> Equal Weight

Reason

Wells Fargo analyst Eva Fortea Verdejo upgraded Bicara Therapeutics to Equal Weight from Underweight with an unchanged price target of $8.

Wells Fargo

Underweight -> Equal Weight

upgrade

2025-05-23

Reason

Wells Fargo

Price Target

2025-05-23

upgrade

Underweight -> Equal Weight

Reason

Wells Fargo upgraded Bicara Therapeutics to Equal Weight from Underweight with an unchanged price target of $8. The form says its Underweight thesis has largely played out on ficerafusp and petosemtamab's head and neck squamous cell carcinomas update. A lower probability of sucess for ficerafusp is largely priced in at current share levels, with a lack of catalysts for upside keeping Bicara range bound in the medium term, the analyst tells investors in a research note.

H.C. Wainwright

Buy

downgrade

$44 -> $41

2025-05-16

Reason

H.C. Wainwright

Price Target

$44 -> $41

2025-05-16

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Bicara Therapeutics to $41 from $44 and keeps a Buy rating on the shares following the Q1 report

See All Ratings

Valuation Metrics

The current forward P/E ratio for Bicara Therapeutics Inc (BCAX.O) is -4.99, compared to its 5-year average forward P/E of -8.19. For a more detailed relative valuation and DCF analysis to assess Bicara Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.19

Current PE

-4.99

Overvalued PE

-4.25

Undervalued PE

-12.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.34

Current EV/EBITDA

-1.31

Overvalued EV/EBITDA

0.88

Undervalued EV/EBITDA

-7.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00